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OBJECTIVE— To find a simple definition of partial remission in type 1 diabetes that reflects
both residual -cell function and efficacy of insulin treatment.
RESEARCHDESIGNANDMETHODS— A total of 275 patients aged16 years were
followed from onset of type 1 diabetes. After 1, 6, and 12 months, stimulated C-peptide during
a challenge was used as a measure of residual -cell function.
RESULTS— By multiple regression analysis, a negative association between stimulated C-
peptide and A1C (regression coefficient0.21, P 0.001) and insulin dose (0.94, P 0.001)
was shown. These results suggested the definition of an insulin dose–adjusted A1C (IDAA1C) as
A1C (percent)  [4  insulin dose (units per kilogram per 24 h)]. A calculated IDAA1C 9
corresponding to a predicted stimulated C-peptide 300 pmol/l was used to define partial
remission. The IDAA1C 9 had a significantly higher agreement (P  0.001) with residual
-cell function than use of a definition of A1C7.5%. Between 6 and 12 months after diagnosis,
for IDAA1C9 only 1 patient entered partial remission and 61 patients ended partial remission,
for A1C 7.5% 15 patients entered partial remission and 53 ended, for a definition of insulin
dose 0.5 units  kg1  24 h1 5 patients entered partial remission and 66 ended, and for
stimulated C-peptide (300 pmol/l) 9 patients entered partial remission and 49 ended. IDAA1C
at 6 months has good predictive power for stimulated C-peptide concentrations after both 6 and
12 months.
CONCLUSIONS— A new definition of partial remission is proposed, including both gly-
cemic control and insulin dose. It reflects residual -cell function and has better stability com-
pared with the conventional definitions.
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C linically, newly diagnosed type 1 di-abetes is characterized by a transientpartial remission period (“honey-
moon”), starting shortly after insulin
treatment is initiated and during which
the patient’s need for exogenous insulin
treatment declines and in some cases even
totally disappears, and metabolic control
is near optimal. The pathogenesis of this
phenomenon has been the subject of dis-
cussion (1) but is likely to be a combina-
tion of two factors: partial -cell recovery
with improved insulin secretion (2) and
improvement of peripheral insulin sensi-
tivity (3).
The definition of the partial remission
period has varied greatly in the past. Most
authors define partial remission as an in-
sulin requirement of 0.5 units  kg1 
24 h1 (4–6). However, it is not useful to
define a disease state by the treatment ap-
plied, and the insulin dose is influenced
by a large number of other factors. At best,
this definition is reasonable when the
treatment policy is uniform, which is
rarely the case, even within single centers
and even less so in a multicenter interna-
tional study. As an extreme consequence
of this definition, a diabetic patient is con-
sidered to be in partial remission when
treated with a relatively low dose of insu-
lin. To correct for this problem, others
have used the definition as an A1C close
to or within the normal range (7). This
definition is also influenced by the treat-
ment, as increasing the insulin dose low-
ers the A1C level. Furthermore, there is
an initial time delay from the time of di-
agnosis of 4 – 6 weeks before a new
steady-state A1C can be achieved (8).
Somewhat more relevant is to combine
the two definitions, that is, an insulin re-
quirement of0.5 units  kg1  24 h1 in
combination with A1C 7.5% (9,10).
Others have used an even lower limit for
insulin requirement such as 0.3 units 
kg1  24 h1 (11). Combining the two
parameters is better than using either one
alone, but having separate limits on each
variable still causes a problem with the
definition because a treatment change
easily influences the classification of a
patient.
As another possibility, Komulainen et
al. (12) used a basal C-peptide level of
100 pmol/l as an index for residual -cell
function. Although fasting C-peptide
alone may be relatively easy to obtain in
research centers and correlates with stim-
ulated C-peptide, it is insufficient for de-
tecting dynamic changes in residual
-cell function. Serial measurements of
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stimulated C-peptide that directly reflect
residual-cell function have therefore be-
come the standard for evaluation of en-
dogenous insulin secretion (13), but no
definitions of partial remission based on
stimulated C-peptide have been pro-
posed. Besides, determination of stimu-
lated C-peptide is a laborious, expensive,
and time-consuming process and is un-
pleasant for the child (the patient has no
breakfast and then undergoes a 90-min
study and delays the morning insulin
dose). Therefore, it would be useful to
have an easy clinical measure for partial
remission somewhat similar to the ho-
meostasis model assessment for insulin
resistance and -cell function (14). The
objective of the current longitudinal in-
vestigation was therefore to evaluate the
relation between A1C and insulin dose,
which are both routinely measured in
clinical practice, to create a surrogate
measure of stimulated C-peptide and
near-normal glycemia. Furthermore, we
aimed to examine the validity and reliabil-
ity of this measure.
RESEARCH DESIGN AND
METHODS— The study was a multi-
center longitudinal investigation in 18 pe-
diatric departments representing 15
countries in Europe and Japan. A total of
275 children and adolescents aged 16
years with newly diagnosed type 1 diabe-
tes presenting to the pediatric depart-
ments between August 1999 and
December 2000 were included in the
study. Exclusion criteria were suspicion
of non–type 1 diabetes (e.g., maturity-
onset diabetes of the young or secondary
diabetes) and initial treatment outside of
the centers for5 days. Diabetes was di-
agnosed according to the World Health
Organization criteria. Of the patients,
84% were white, mean  SD age at clin-
ical diagnosis was 9.1  3.7 years, and
BMI was 16.5  3.2 kg/m2. Insulin regi-
mens were recorded 1, 3, 6, 9, and 12
months after diagnosis. After 12 months,
52.9% of the children were taking insulin
twice daily, 25% three times daily, and
18.5% four or more times daily. Only a
few children (3.3%) received one insulin
injection daily. A premixed form of insu-
lin was used in 72.3% of the children tak-
ing insulin twice daily. Only three
children used an insulin infusion pump,
and 13% were treated with a rapid-acting
insulin analog. The mean daily insulin dose
was 0.7  0.3 units/kg. For the new mea-
sure to cover different insulin policies, local
centers were not instructed to follow a spe-
cific insulin treatment program.
The study was performed according
to the criteria of the Helsinki II Declara-
tion (15) and was approved by the local
ethics committee in each center. All of the
patients and their parents or guardians
gave informed consent.
A1C
Samples for A1C analysis were collected
at onset and after 1, 3, 6, 9, and 12
months at each department using the Bio-
Rad A1C sample preparation kit (Bio-Rad
Laboratories, Munich, Germany) and
mailed to the Steno Diabetes Centre
(Copenhagen, Denmark) as described be-
fore (16). The A1C analysis was per-
formed by automatic high-pressure liquid
chromatography with the same calibrator
lots as used in the Diabetes Control and
Complications Trial (DCCT) to facilitate
comparisons with this study. Normal
range for A1C for the method at Steno
Diabetes Center was 4.4–6.3% (0.3%
higher than the DCCT method).
C-peptide
After 1, 6, and 12 months of diabetes, a
standard liquid meal was used to stimu-
late endogenous C-peptide release (17).
Serum samples were labeled and frozen at
–20°C until shipment on dry ice to the
Steno Diabetes Centre for the determina-
tion of C-peptide within 6 months. Sam-
ples were thawed only once for RIA
determination. Serum C-peptide was an-
alyzed by a fluoroimmunometric assay
(AutoDELFIA C-peptide; PerkinElmer
Life and Analytical Sciences, Turku, Fin-
land). The analytical sensitivity was better
than 5 pmol/l, the intra-assay coefficient
of variation was 6% at 20 pmol/l, and
recovery of standard, added to plasma be-
fore extraction, was 100% when cor-
rected for losses inherent in the plasma
extraction procedure.
Statistics
A1C and insulin dose cannot be consid-
ered separately because the measured
A1C will be influenced by the insulin dose
as well as by the residual -cell function.
The idea was to combine the two to sug-
gest a new measure of insulin dose–
adjusted A1C (IDAA1C) that was
relatively less influenced by treatment
policy. A unified suggestion, in which
both A1C and insulin dose were included,
was investigated by multiple regression
analysis with the logarithm of stimulated
C-peptide as the dependent variable and
sex, age, A1C, and daily insulin dose
(units per kilogram body weight) as inde-
pendent variables 6 and 12 months after
diagnosis.
In the DCCT, a limit of 300 pmol/l
was defined as the level for “the C-peptide
responders” (200 –500 pmol/l). We
aimed to define partial remission in align-
ment with the DCCT (17) as an IDAA1C
predicting a C-peptide response of300
pmol/l.
To investigate the influence of age on
the proportion of patients in remission,
the insulin requirement and A1C values
during the follow-up were analyzed with
the patients divided into age-groups (0–
4.9, 5.0–9.9, and 10.0–16 years). Age-
group comparisons versus IDAA1C 9
were done by a 	2 test for the count of
patients.
To compare the various definitions,
the proportion of children in partial re-
mission as defined by each definition was
evaluated at 3, 6, 9, and 12 months. The
insulin dose used to calculate the rate of
partial remission was the value before the
visit because A1C reflects the blood glu-
cose level over the previous 4- to 6-week
period (8).
A statistical comparison was per-
formed to evaluate the concurrent agree-
ment of A1C, IDAA1C, and stimulated
C-peptide. Agreement between the defi-
nitions was examined by plotting 12-
month values for stimulated C-peptide
against both A1C and IDAA1C and with
summary statistics for the percentage of
agreement with stimulated C-peptide.
This latter comparison was supplemented
with a formal 	2 test of which parameters
of A1C or IDAA1C are most closely re-
lated to C-peptide, by constructing a 2
2  2 table of classifications based on
A1C, IDAA1C, and stimulated C-peptide.
In this table, we tested whether A1C7.5
or7.5% had an influence on stimulated
C-peptide when the IDAA1C classifica-
tion was included. For each IDAA1C
group (9, respectively, 9) this con-
sisted of a test of independence of A1C
group and stimulated C-peptide group. A
similar test was done with A1C and
IDAA1C with reversed roles. The two test
statistics were then added to obtain a joint
conclusion regarding which of the two
measures gave the best agreement with
the C-peptide definition.
To confirm the validity of IDAA1C at
12 months, the relationship of stimulated
C-peptide and IDAA1C at 6 and 12
months was investigated by linear regres-
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sion according to duration and IDAA1C
but not sex and age. To examine the pre-
dictive validity of IDAA1C, A1C and in-
sulin dose data from 1 and 6 months were
used in a multiple regression model (in-
cluding covariates age and sex) to predict
C-peptide responses (logarithmic scale)
at 6 and 12 months, respectively. To ex-
amine the agreement between the two
definitions (IDAA1C 9 and stimulated
C-peptide 300 pmol/l), a 	2 test was
performed in the 2 2 table of classifica-
tions based on IDAA1C and stimulated
C-peptide. The stability of the IDAA1C-
defined partial remission was investigated
by comparing the number of subjects
transitioning in and out of partial remis-
sion defined by IDAA1C and by other def-
initions of partial remission over the
period of 6–12 months.
Statistical analyses were performed
using SAS (version 9.1; SAS Institute,
Cary, NC). P  0.05 was considered
significant.
RESULTS
Partial remission defined by IDAA1C
The multivariate analysis showed a nega-
tive correlation between stimulated C-
peptide, A1C, and insulin dose, with a
significant effect of age (estimate 0.09/
year, P  0001) but not sex (estimate
comparing female with male patients
0.01, P
 0.91) at 6 months after diag-
nosis. It would be natural to include an
age effect in the formula, if the aim of the
study had purely been to predict the stim-
ulated C-peptide level. However, because
the purpose was to suggest a new measure
for remission, it was anticipated that
the suggested formula for IDAA1C could
be useful on its own and therefore age was
not included. From the regression coeffi-
cients at 6 months (A1C0.21 and insu-
lin dosage 0.94), it was seen that there
was a factor of 4.4 between the coeffi-
cients for these parameters. The R2 value
was 0.30. Results at 6 and 12 months
were similar. This finding inspired the
suggestion of a combined expression of
insulin dose and A1C, formulated as a
specific definition of the IDAA1C
 A1C
(percent)  4  [insulin dose (units per
kilogram per 24 h)]. The factor of 4.4 was
substituted by 4 to obtain simple num-
bers. Based on the slope of the regression
line between stimulated C-peptide, A1C,
and insulin dose, a predicted C-peptide
value can be calculated from any given set
of corresponding A1C and insulin dose.
The distribution of patients according to
individual A1C and insulin dosages at 6
months’ duration are shown in Fig. 1A, in
which each diagonal red line corresponds
to one IDDA1C value. According to this
model an IDAA1C threshold 9 corre-
sponds to a predicted level of 300
pmol/l for the corresponding stimulated
C-peptide. This expression can be used as
a qualitative measure of partial remission,
and in alignment with the DCCT “C-
peptide responders” (200–500 pmol/l),
we have chosen IDAA1C 9 to define
partial remission. Other threshold values
Partial remission in new-onset type 1 diabetes
1386 DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009
for IDAA1C could have been chosen, cor-
responding to different predicted C-
peptide values. Compared with the partial
remission definition, insulin dose 0.5
units  kg1  24 h1 and A1C 7.5%
(Fig. 1A, rectangular dashed box), our
definition has been extended with the tri-
angular area above and to the right side of
the rectangular dashed box. As an indica-
tor of more aggressive insulin therapy at
some of the centers, there are more pa-
tients placed in the triangle to the right of
the dashed line that marks an insulin dose
0.5 units  kg1  24 h1 than in the
upper triangle above the dashed line,
marking an A1C 7.5%.
Partial remission by IDAA1C and
influence of age
Figure 1B shows that age at onset influ-
ences the rate of partial remission in chil-
dren with type 1 diabetes. Significantly
(P  0.05) fewer patients in the young
age-group (0–5 years) were in partial re-
mission (3–9 months, P  0.01) com-
Figure 1—A: The thresholds for partial remission based on IDAA1C9 (solid green line) and A1C7.5% and insulin doses0.5 units  kg1 
24 h1 (rectangular dashed box). Each diagonal red line corresponds to one IDAA1C value. The numbers in boxes are the predicted values for
stimulated C-peptide concentrations for a 10-year-old boy at the relevant IDAA1C value and, as illustrated, other threshold values for IDAA1C
correspond to different predicted C-peptide values. The signs give the distribution of 257 patients with type 1 diabetes after 6 months’ duration. B:
Age at onset influences the rate of partial remission as assessed by IDAA1C in children with type 1 diabetes. The proportion of partial remission is
lowest in the youngest age-group (0–4.9 years). Because of lower insulin sensitivity, the proportions of partial remission in the old age-group (10
years) and the school-age children (5–9.9 years) seem to be similar despite higher residual -cell function. C: The proportion of children in partial
remission according to the different definitions. From 3 to 12 months, the curves for IDAA1C (curve 1), C-peptide (curve 2), and insulin dose (curve
4) show close agreement. Using the new definition, partial remission occurred in 61% at 3 months, in 44% at 6 months, and in 18% after 12 months.
D: Agreement between definitions of those in partial remission, A1C 7.5% (left panel, dashed vertical line), IDAA1C 9 (right panel, dashed
vertical line), and stimulated C-peptide300 pmol/l (dashed horizontal line) at 12 months. The arrows point to the areas showing that A1C7.5%
disagrees significantly more than IDAA1C9 with C-peptide300 pmol/l, probably because the children receive more exogenous insulin, which is
accounted for in the insulin dose–adjusted model. E: The relationship of IDAA1C9 (dashed vertical line) and stimulated C-peptide300 pmol/l
(dashed horizontal line) at 6 and 12 months. Individual observations are shown by age-groups. The regression lines for 6 (——) and 12 (– – –)
months show the linear correlation of IDAA1C and C-peptide over a continuum of stimulated C-peptide values.
Mortensen and Associates
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pared with those in the older age-groups.
After 12 months, only 5% of the very
young children are in partial remission
compared with 20% of those in the older
age-groups.
Comparison of partial remission by
IDAA1C with existing definitions
The proportion of children in partial re-
mission according to various definitions
is shown in Fig. 1C as a function of dia-
betes duration. Because the A1C level at 1
month still reflects glycemia before diag-
nosis, the comparison between the differ-
ent definitions of partial remission was
performed at 3 months. From 3 to 12
months, the curves for IDAA1C (curve 1),
C-peptide (curve 2), and insulin dose
(curve 4) show close agreement. The def-
inition of partial remission including in-
sulin dose0.5 units  kg1  24 h1 and
A1C7.5% (curve 5) suggests that fewer
patients are in partial remission, and A1C
7.5% without insulin dose adjustment
(curve 3) suggests that more patients are
in partial remission after 3 months. Using
the new definition, partial remission oc-
curred in 61% at 3 months, in 44% at 6
months, and in 18% after 12 months.
Agreements between A1C, IDAA1C,
and stimulated C-peptide
The agreement between definitions of
those in partial remission by A1C7.5%
and by IDAA1C9 compared with resid-
ual -cell function with C-peptide 300
pmol/l is shown in Fig. 1D. The defini-
tions agree in the upper left quadrant and
the lower right quadrant of the diagrams.
However, for A1C (Fig. 1D, left panel)
there are significantly more patients in the
lower left quadrant of the diagram with an
A1C 7.5% but with a residual -cell
function 300 pmol/l than for IDAA1C
(Fig. 1D, right panel), probably because
the children with low residual -cell
function who are receiving aggressive in-
sulin treatment are more accurately ac-
counted for in the dose-adjusted model
(see formal 	2 test in the next paragraph).
A formal test of the strength of the rela-
tionship between each definition and
stimulated C-peptide at 6 months was
performed in a model, in which the clas-
sifications of partial remission according
to both A1C and IDAA1C were allowed
an effect on the C-peptide definition of
partial remission (300 pmol/l).
In the joint test, A1C was not signifi-
cant (	2
 2.40, 2 df, P
 0.30), whereas
IDAA1C was clearly significant (	2 

11.07, 2 df, P 
 0.004).Thus, IDAA1C
gives the best agreement with the C-
peptide definition. The same conclusion
was reached after 12 months.
Correlation between IDAA1C and
actual C-peptide response at 6 and
12 months
The relationship of IDAA1C and stimu-
lated C-peptide at 6 and 12 months is
shown in Fig. 1E. The regression curves
suggest a tendency toward higher stimu-
lated C-peptide values at 6 months com-
pared with 12 months, also when related
to IDAA1C. Overall, the predictive value
of IDAA1C in combination with sex and
age was good (R2 
 0.30 at 6 months
and R2 
 0.31 at 12 months).
IDAA1C at 1 and 6 months as
predictor of future values of
C-peptide response
In predicting C-peptide after 6 months
based on 1 month of data and after 12
months based on 6 months of data, using
sex, age, A1C, and insulin dose, we found
that there was a significant dependence
on both A1C and insulin dose, but the
effect of these could be adequately sum-
marized by the IDAA1C. The coefficients
in the final model for predicting (log) C-
peptide after 12 months was sex (estimate
for female patients0.11, P
 0.40), age
(estimate 0.13, P  0.001), and IDAA1C
after 6 months (estimate 0.32, P 
0.001).
Stability of IDAA1C-defined partial
remission in the prepubertal
compared with older age-groups
Only a few of the very young children
(0–4 years) are in partial remission using
any of the two definitions (stimulated C-
peptide 300 pmol/l or IDAA1C 9).
The older children (10–16 years) have
relatively higher C-peptide values; thus,
the patients, who are in partial remission
according to C-peptide but not IDAA1C,
are mostly older and presumably with
more insulin resistance due to puberty,
whereas those who are not in partial re-
mission according to C-peptide but are in
partial remission according to IDAA1C
are in the prepubertal group (5–9 years)
with better insulin sensitivity. The two
definitions agree for 71.4% of the prepu-
bertal and the older group of patients (av-
erage for 6- and 12-month values).
Stability of definitions
During the period 6–12 months after di-
agnosis, the change in frequency of partial
remission as assessed by IDAA1C, A1C,
insulin dose, and stimulated C-peptide is
illustrated in Table 1. With IDAA1C 9,
only 1 patient entered partial remission
and 61 patients ended partial remission;
with A1C 7.5%, 15 entered partial re-
mission and 53 ended; with insulin dose
0.5 units  kg1  24 h1, 5 entered par-
tial remission and 66 ended; and with
stimulated C-peptide (300 pmol/l), 9
entered partial remission and 49 ended.
CONCLUSIONS— We have sug-
gested a novel definition: A1C (%) [4
insulin dose (units per kilogram per
24 h)]9 for the partial remission period
in children and adolescents with type 1
diabetes (Fig. 1A). This practical and sim-
ply calculated definition is useful as it re-
lates insulin dose and measured A1C to
the preservation of -cell function (C-
peptide levels). This measure, adjusting
for exogenous insulin, can be used as a
quantitative measure of the underlying
and theoretically untreated disease, and
in this setting, it is superior to a definition
using A1C alone.
This definition also avoids the neces-
sity of measurement of C-peptide levels,
which is laborious, expensive, and often
unavailable. Generally, there was good
agreement between these two measures
(IDAA1C and C-peptide) (Fig. 1C), al-
though we saw a different pattern over age
(Fig. 1B and E), as discussed below. With
either A1C 7.5% or IDAA1C 9, the
Table 1—Partial remission transitions from 6 to 12 months
PR definition
In PR at
6 months/proportion
in PR at 12 months
Not in PR at
6 months/proportion
in PR at 12 months
IDAA1C 9 37/98 (38) 1/122 (1)
A1C 7.5% 87/140 (62) 15/85 (18)
Insulin dose 0.5 units  kg1  24 h1 46/112 (41) 5/123 (4)
C-peptide 300 pmol/l 58/107 (54) 9/119 (8)
Data are n (%). PR, partial remission.
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maximum partial remission in all age-
groups was reached at 3 months after
diagnosis (Fig. 1B), which is in accor-
dance with other studies (11,18). In ad-
dition, the IDAA1C correctly identified
those in partial remission from the very
start, whereas a partial remission defini-
tion by insulin dosage0.5 units  kg1 
24 h1 misclassifies a proportion of pa-
tients early in the disease because of a lack
of or delay in insulin treatment around
the time of diagnosis (Fig. 1C). This mis-
classification may be of importance for se-
lection of patients for intervention studies
aimed to protect islet cell function. Be-
cause IDAA1C is based on a joint evalua-
tion of C-peptide, A1C, and insulin dose,
the agreement of those in partial remis-
sion by the C-peptide definition is better
for IDAA1C than for A1C alone (Fig. 1D),
which was also shown in the 	2 test of the
relationship between the two measures
and stimulated C-peptide.
Interestingly, the residual-cell func-
tion was highest in the age-group 10–15
years during the whole study period, and
this finding is comparable to the observa-
tions of the U.S. multicenter national
study group, Type 1 Diabetes TrialNet
(13). However, the new definition indi-
cates that the frequency of partial remis-
sion was not higher in this group of
patients compared with the school-age
children 5–10 years old. Likewise, the mean
daily insulin dose was higher in the older
age-group (10 –15 years) than in the
younger age-group (5–10 years), perhaps
indicating higher insulin resistance dur-
ing puberty (19). Thus, the degree of hy-
perglycemia is determined not only by the
-cell function or insulin resistance but
also by results from a combination of
these two factors, which is reflected in the
new definition. Therefore, IDAA1C was
in agreement with stimulated C-peptide
in 71.4% of the prepubertal and older pa-
tients in partial remission (Fig. 1E).
It is important to know the relation-
ship of IDAA1C and stimulated C-peptide
during the 1st year in new-onset type 1
diabetes. Overall IDAA1C showed a good
correlation with the residual -cell func-
tion as assessed by stimulated C-peptide
(R2 
 31%). This agreement level com-
pares well with the homeostasis model as-
sessment (14) in which estimates of-cell
function correlated with those for the hy-
perglycemic clamp (37%) and the intra-
venous glucose tolerance test (41%). In
addition, IDAA1C at 6 months was the
best predictor of stimulated C-peptide
concentrations at 6 and 12 months com-
pared with A1C and insulin dose. This
result shows that IDAA1C overall is a
good estimate of stimulated C-peptide in
type 1 diabetes.
In terms of stability over time, only
one patient was found to enter partial re-
mission between 6 and 12 months. When
spontaneous partial remission occurs in
prepubertal or pubertal patients, it occurs
most often within the first 4 months and
infrequently after 6 months (20,21). This
is a strong endorsement of the new
IDAA1C definition because all other def-
initions discussed have higher numbers of
patients that seem to enter partial remis-
sion in the period from 6 to 12 months
(Table 1).
The new formula is very easy and
practical to use in the clinic where a dia-
betes nurse specialist takes care of many
aspects of daily management during the
first months after diagnosis. At each visit
in the outpatient clinic, the IDAA1C can
be calculated by the nurse to check that
the patient is still in remission, particu-
larly if he or she does not frequently mea-
sure blood glucose or record data. If this is
not the case, the patient may need to be
referred to a pediatric diabetologist for
changes in insulin management. Already
this measurement has improved the de-
livery of diabetes care in some of our clin-
ics and has led to a smooth transition to
more individual treatment regimens.
Direct measurement of C-peptide has
been recommended to provide the most
appropriate primary outcome in trials
evaluating the efficacy of therapies to pre-
serve -cell function (13). The new
IDAA1C should be beneficial for research
in this area because it might remove the
need for intrusive investigations. It takes
into account the glycemic consequences
of a change in residual -cell function.
C-peptide measurements alone do not
provide this information. In addition, the
model should make it easier to select chil-
dren and adolescents with significant en-
dogenous insulin production and
evaluate clinically meaningful changes in
intervention therapies (22) that are aimed
to preserve/regenerate -cell function in
new-onset type 1 diabetes.
In summary, the new insulin dose–
adjusted definition of the partial remis-
sion period gives the best agreement with
the stimulated C-peptide definition, is
convenient and easy to use, and is associ-
ated with a stimulated C-peptide re-
sponse of 300 pmol/l.
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